A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
33 Downloads (Pure)

Abstract

Introduction: The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into the current status of HEM in PM, in order to identify if and how modeling methods are used to address the challenges described in literature.

Areas covered: A review was performed on studies that simulate health economic outcomes for personalized clinical pathways. Decision tree modeling and Markov modeling were the most observed methods. Not all identified challenges were frequently found, challenges regarding companion diagnostics, diagnostic performance, and evidence gaps were most often found. However, the extent to which challenges were addressed varied considerably between studies.

Expert commentary: Challenges for HEM in PM are not yet routinely addressed which may indicate that either (1) their impact is less severe than expected, (2) they are hard to address and therefore not managed appropriately, or (3) HEM in PM is still in an early stage. As evidence on the impact of these challenges is still lacking, we believe that more concrete examples are needed to illustrate the identified challenges and to demonstrate methods to handle them.
Original languageEnglish
Pages (from-to)17-25
Number of pages9
JournalExpert review of pharmacoeconomics & outcomes research
Volume17
Issue number1
DOIs
Publication statusPublished - 27 Dec 2017

Fingerprint

Precision Medicine
Checklist
Economics
Health
Decision Trees
Molecular Imaging
Critical Pathways
Decision Support Techniques
Health Status
Medicine

Keywords

  • METIS-320536
  • IR-102915

Cite this

@article{db5de393e8a94ce6b348aa5886764e48,
title = "A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models",
abstract = "Introduction: The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into the current status of HEM in PM, in order to identify if and how modeling methods are used to address the challenges described in literature.Areas covered: A review was performed on studies that simulate health economic outcomes for personalized clinical pathways. Decision tree modeling and Markov modeling were the most observed methods. Not all identified challenges were frequently found, challenges regarding companion diagnostics, diagnostic performance, and evidence gaps were most often found. However, the extent to which challenges were addressed varied considerably between studies.Expert commentary: Challenges for HEM in PM are not yet routinely addressed which may indicate that either (1) their impact is less severe than expected, (2) they are hard to address and therefore not managed appropriately, or (3) HEM in PM is still in an early stage. As evidence on the impact of these challenges is still lacking, we believe that more concrete examples are needed to illustrate the identified challenges and to demonstrate methods to handle them.",
keywords = "METIS-320536, IR-102915",
author = "Koen Degeling and Hendrik Koffijberg and IJzerman, {Maarten Joost}",
year = "2017",
month = "12",
day = "27",
doi = "10.1080/14737167.2017.1273110",
language = "English",
volume = "17",
pages = "17--25",
journal = "Expert review of pharmacoeconomics & outcomes research",
issn = "1473-7167",
publisher = "Taylor & Francis",
number = "1",

}

TY - JOUR

T1 - A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine

T2 - towards implementing patient-level models

AU - Degeling, Koen

AU - Koffijberg, Hendrik

AU - IJzerman, Maarten Joost

PY - 2017/12/27

Y1 - 2017/12/27

N2 - Introduction: The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into the current status of HEM in PM, in order to identify if and how modeling methods are used to address the challenges described in literature.Areas covered: A review was performed on studies that simulate health economic outcomes for personalized clinical pathways. Decision tree modeling and Markov modeling were the most observed methods. Not all identified challenges were frequently found, challenges regarding companion diagnostics, diagnostic performance, and evidence gaps were most often found. However, the extent to which challenges were addressed varied considerably between studies.Expert commentary: Challenges for HEM in PM are not yet routinely addressed which may indicate that either (1) their impact is less severe than expected, (2) they are hard to address and therefore not managed appropriately, or (3) HEM in PM is still in an early stage. As evidence on the impact of these challenges is still lacking, we believe that more concrete examples are needed to illustrate the identified challenges and to demonstrate methods to handle them.

AB - Introduction: The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into the current status of HEM in PM, in order to identify if and how modeling methods are used to address the challenges described in literature.Areas covered: A review was performed on studies that simulate health economic outcomes for personalized clinical pathways. Decision tree modeling and Markov modeling were the most observed methods. Not all identified challenges were frequently found, challenges regarding companion diagnostics, diagnostic performance, and evidence gaps were most often found. However, the extent to which challenges were addressed varied considerably between studies.Expert commentary: Challenges for HEM in PM are not yet routinely addressed which may indicate that either (1) their impact is less severe than expected, (2) they are hard to address and therefore not managed appropriately, or (3) HEM in PM is still in an early stage. As evidence on the impact of these challenges is still lacking, we believe that more concrete examples are needed to illustrate the identified challenges and to demonstrate methods to handle them.

KW - METIS-320536

KW - IR-102915

U2 - 10.1080/14737167.2017.1273110

DO - 10.1080/14737167.2017.1273110

M3 - Article

VL - 17

SP - 17

EP - 25

JO - Expert review of pharmacoeconomics & outcomes research

JF - Expert review of pharmacoeconomics & outcomes research

SN - 1473-7167

IS - 1

ER -